CVM

#4465
Cel-Sci Corporation
4.3300 USD
+7.96%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
4.1800
4.3300
1年のレンジ
3.0164
5.1500
1日の変化
+7.96%
月次変化
+20.28%
6か月変化
-15.92%
1年の変化
-15.92%
以前の終値
4.0106
始値
4.1800
Bid
Ask
安値
4.1800
High
4.3300
ボリューム
5
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 36.623 M
  • Employee 44
  • Founded N/A
  • CEO N/A
  • Website www.cel-sci.com
  • Headquarter Colorado, United States
  • FIGI BBG000H5G6L5
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-1.47
売上高対価格比率
-57.5

Cel-Sci Corporation

Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint.

ニュース